Cogent Biosciences Shares Rise on Positive Phase 3 Trial Results

Cogent Biosciences shares are trading higher after the company reported positive results from its Phase 3 PEAK trial of bezuclastinib for imatinib-resistant GIST patients, demonstrating significant improvement in progression-free survival and objective response rate.